EBC-46

EBC-46

Fontainea picrosperma: Botany, Wild Range, and Global Cultivation Success

The Blushwood tree grows wild only in north Queensland's rainforest, but controlled cultivation has proven viable across Australia and Asia — opening the door to scalable, sustainable supply of tigilanol tiglate.

EBC-46

Phase I Safety Trial for Tigilanol Tiglate: What the Human Data Shows

The first-in-human Phase I trial of tigilanol tiglate demonstrated localised anti-tumour responses with a clean systemic safety profile — a result that immediately distinguished EBC-46 from prior PKC-targeting drugs.

EBC-46

PKC-Delta Activation: The Molecular Switch EBC-46 Flips

Tigilanol tiglate activates PKC-delta by mimicking the diacylglycerol second messenger, triggering simultaneous vascular disruption, immune cascade, and cancer-cell apoptosis within the tumour.

EBC-46

Stelfonta's FDA Approval: What It Means for Human Oncology Research

The FDA's full approval of Stelfonta validated tigilanol tiglate's PKC-activation mechanism for the first time, creating regulatory precedent that directly accelerates human oncology trials.

EBC-46

The Unmapped Phytochemistry of the Blushwood Berry: What Else Lies Beyond EBC-46

Tigilanol tiglate is just one compound in the Blushwood berry — the full phytochemical profile of Fontainea picrosperma remains largely uncharacterised and scientifically fascinating.

EBC-46

Blood Markers, Doctor Reactions, and the Blushwood Reports That Demand Scientific Attention

When doctors look up blushwood extract after seeing unexplained improvements in their patients' blood work, these are not casual testimonials — they are clinical signals worth investigating.

EBC-46

Biomarker Endpoints in EBC-46 Clinical Research: Measuring What Matters Beyond Tumour Shrinkage

Modern EBC-46 trials are incorporating biomarker endpoints that capture immune activation, vascular disruption, and tissue remodelling — painting a richer picture than tumour size alone.

EBC-46

PKC Isoforms and Mitochondrial Energy Metabolism: How EBC-46 May Influence Cellular Bioenergetics

PKC-delta and PKC-epsilon isoforms play opposing roles in mitochondrial function — EBC-46's selective activation may reshape cellular energy production beyond tumour destruction.

EBC-46

Compassionate Use Pathways: How EBC-46 Could Reach Patients Before Full Approval

Regulatory frameworks for compassionate use and expanded access could allow tigilanol tiglate to reach patients with unmet needs well before Phase III completion.

EBC-46

One Year and Beyond: What Long-Term Blushwood Extract Users Are Reporting

After a year or more of daily blushwood extract use, a cohort of verified buyers report sustained reductions in inflammation, improved energy, and unexpected clinical observations their doctors found difficult to explain.

EBC-46

Seasonal Yield and Tigilanol Tiglate Concentration: What Drives Variation in Blushwood Fruit Chemistry

Tigilanol tiglate concentration in Fontainea picrosperma fruit varies with season, rainfall, plant maturity, and growing environment — a fact with profound implications for supply chain and cultivation strategy.

EBC-46

Dose Escalation in Tigilanol Tiglate Trials: Optimising the Intratumoral Injection

Determining the right intratumoral dose of tigilanol tiglate required solving problems unique to locally-delivered agents — from volume calculation to defining dose-limiting toxicity at the injection site.